Overview

* Bio-Rad Q2 2025 revenue rises 2.1% yr/yr, beating analyst expectations

* Adjusted EPS for Q2 2025 beats consensus, reflecting effective expense management

* Co completes acquisition of Stilla Technologies, enhancing Droplet Digital PCR offerings

Outlook

* Bio-Rad ( BIO/B ) expects full-year revenue growth of 0 to 1.0 percent

* Company revises full-year operating margin to 12.0 to 13.0 percent

Result Drivers

* PROCESS CHROMATOGRAPHY - Increased sales of process chromatography products drove revenue growth

* DIABETES TESTING REIMBURSEMENTS - Lower reimbursements for diabetes testing in China impacted Clinical Diagnostics segment sales

* ACQUISITION IMPACT - Acquisition of Stilla Technologies expanded Droplet Digital PCR offerings, contributing to revenue growth

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Sales Beat $651.60 $615.20

mln mln (6

Analysts

)

Q2 Beat $2.61 $1.73 (6

Adjusted Analysts

EPS )

Q2 EPS $11.67

Q2 Net $317.80

Income mln

Q2 Gross 53.0%

Margin

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

* Wall Street's median 12-month price target for Bio Rad Laboratories Inc ( BIO/B ) is $317.50, about 21.2% above its July 30 closing price of $250.08

* The stock recently traded at 28 times the next 12-month earnings vs. a P/E of 24 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)